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Abstract
Background: Rapid reviews are an accelerated evidence synthesis approach intended to meet the timely needs of
decision-makers in healthcare settings. Quality of conduct and reporting has been described in the rapid review
literature; however, no formal assessment has been carried out using available instruments. The objective of this
study was to explore compliance with conduct and reporting guidelines in rapid reviews published or posted
online during 2013 and 2014.
Methods: We performed a comprehensive literature search for rapid reviews using multiple bibliographic databases
(e.g. PubMed, MEDLINE, EMBASE, the Cochrane Library) through December 31, 2014. Grey literature was searched
thoroughly, and health technology assessment agencies were surveyed to identify additional rapid review products.
Candidate reviews were assessed for inclusion using pre-specified eligibility criteria. Detailed data was collected
from the included reviews on study and reporting characteristics and variables significant to rapid reviews (e.g.
nomenclature, definition). We evaluated the quality of conduct and reporting of included rapid reviews using the A
Measurement Tool to Assess Systematic Reviews (AMSTAR) and Preferred Reporting Items for Systematic Reviews
and Meta-Analyses (PRISMA) checklists. Compliance with each checklist item was examined, and the sum of
adequately reported items was used to describe overall compliance. Rapid reviews were stratified to explore
differences in compliance related to publication status. The association between compliance and time to
completion or length of publication was explored through univariate regression.
Results: Sixty-six rapid reviews were included. There were heterogeneous nomenclature, research questions and
approaches to rapid reviews. Compliance with AMSTAR and PRISMA checklists was poor. Published rapid reviews
were compliant with individual PRISMA items more often than unpublished reviews, but no difference was seen in
AMSTAR item compliance overall. There was evidence of an association between length of publication and time to
completion and the number of adequately reported PRISMA or AMSTAR items.
Conclusions: Transparency and inadequate reporting are significant limitations of rapid reviews. Scientific editors,
authors and producing agencies should ensure that the reporting of conduct and findings is accurate and
complete. Further research may be warranted to explore reporting and conduct guidelines specific to rapid reviews
and how these guidelines may be applied across the spectrum of rapid review approaches.
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Background
Healthcare decision-makers at all levels are under con-
stant pressure to make timely evidence-informed policy
or practice decisions. Although highly valued, the time
needed to complete a full systematic review of the litera-
ture often exceeds the time that end-users have to evalu-
ate evidence or incorporate it into their processes. Rapid
reviews are an accelerated evidence synthesis approach
specifically intended to meet the needs of knowledge
users in healthcare settings [1, 2]. Ideally, to minimize
potential sources of bias, a rapid review should follow
frameworks for systematic review conduct, such as those
published by the Cochrane Collaboration, as closely as
time will allow. However, in order to pragmatically
achieve timely delivery of evidence, certain concessions
are often made in these processes. Attempts have been
made to describe and assess rapid reviews through selec-
tion and careful appraisal of exemplar samples [1, 3–6].
The characteristics of rapid reviews, and the limitations
of these products, have been described in previous work
[1, 6, 7]. Heterogeneity of rapid review approaches and
poor reporting of methods or processes have been con-
sistently observed, making evaluation of these evidence
products difficult [6]. This, in turn, makes it difficult for
decision-makers to quantify any bias that may have been
introduced or to judge how much value to place on the
evidence contained in a rapid review.
Rapid reviews are created by a variety of producers
worldwide, including individuals, independent research
groups, and organizations and agencies, which offer
rapid evidence services to their stakeholders. Many rapid
review products are not published, and the majority are
not indexed in health-related bibliographic databases
(e.g. MEDLINE, CINAHL) [7]. The diverse nomencla-
ture used to describe these approaches also makes it dif-
ficult to identify rapid reviews using traditional search
methods. This is complicated further by the lack of an
accepted or validated definition for rapid reviews, which
results in the term ‘rapid review’ having different mean-
ings to the assortment of stakeholders who produce or
use them [2, 8].
There are currently no guidelines or accepted rules for
the reporting or conduct of rapid reviews. The Preferred
Reporting Items of Systematic Reviews and Meta-
Analyses (PRISMA) statement and the A Measurement
Tool to Assess Systematic Reviews (AMSTAR) checklist
are reliable and practical instruments designed to help
end-users discriminate between systematic reviews with
a focus on quality of reporting and conduct [9, 10]. Both
have become widely accepted by publishing agencies and
evidence producers since 2011. Given the aim of rapid
reviews to optimize to the extent possible a systematic
process while synthesizing evidence and balancing the
timely requirements of healthcare decision-making, it is
feasible that these tools could also be applied to rapid
reviews. No studies to date have applied validated
reporting or conduct instruments such as PRISMA or
AMSTAR to rapid reviews with the goal of assessing the
quality of conduct and reporting, although previous
work has suggested this task may be helpful to improve
reporting transparency [4].
Given the above, and the importance of rapid reviews
to decision-makers, this study was carried out to explore
the general study characteristics of these research prod-
ucts. We also aimed to evaluate the quality of both
process and reporting in both journal-published and
unpublished (grey literature) rapid evidence synthesis
products through measurement of compliance with the
PRISMA and AMSTAR checklists. The secondary aims
were to explore whether the time to completion or the
length of the report influenced instrument compliance.
Methods
The strategy for locating rapid reviews and assessing the
quality of their conduct and reporting involved three
fundamental steps. First, a protocol was developed in
August 2011 in consultation with methodological ex-
perts in knowledge synthesis, health technology assess-
ment (HTA), and evidence-based decision-making.
Second, a broad and comprehensive literature search
was carried out to identify published and unpublished
samples of rapid reviews produced internationally since
2005. Third, an in-depth examination of the characteris-
tics of the included rapid reviews was conducted. We
examined the quality of reporting and process for both
published and unpublished rapid reviews using validated
tools (AMSTAR and PRISMA) and compared the results
to identify areas for improvement. In addition, we
explored a variety of common themes identified in previ-
ously published work in the area of accelerated evidence
synthesis.
Information sources
Comprehensive literature searches were conducted with
the assistance of an experienced medical information
specialist knowledgeable in evidence synthesis and rapid
reviews. Search strategies were peer-reviewed [11] and
used both controlled vocabulary (e.g. National Library of
Medicine’s MeSH terms) and keywords. Between Octo-
ber 25 and 31, 2011 we searched PubMed, MEDLINE
(Ovid MEDLINE(R) In-Process & Other Non-Indexed
Citations, Ovid MEDLINE(R) Daily and Ovid MEDLI-
NE(R) 1948 to Present;), EMBASE (Ovid, 1980 to 2011
Week 42), the Cochrane library, York Centre for Re-
views and Dissemination (CRD) Database of Abstracts of
Reviews of Effects (DARE), NHS Economic Evaluation
Database (EED) and HTA, Web of Science, National Li-
brary of Medicine Gateway, and CINAHL (EBSCOHost).
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Search updates were carried out monthly until Decem-
ber 31, 2014 (see Additional file 1).
A thorough grey literature search was conducted using
CADTH’s Grey matters: A search tool for evidence-
based medicine (https://www.cadth.ca/resources/finding-
evidence/grey-matters-practical-search-tool-evidence-
based-medicine) to identify rapid reviews not formally
published in peer-reviewed journals and rapid reviews
produced by organizations and agencies whose products
are not indexed in the bibliographic databases searched.
The grey literature search was augmented by a general
Internet search (Google/Google Scholar) to identify
web-based reports. The searches were supplemented by
reviewing the bibliographies of key papers and confer-
ence proceedings, citation mapping and hand searching
of HTA agencies known to deliver rapid review services.
The searches were large in scope and intentionally unre-
stricted in order to capture the wide variety of published
and unpublished products falling under the global term
of ‘rapid review’.
Scan of HTA agency rapid reviews
In order to more comprehensively identify rapid review
producers, we supplemented the formal literature search
with an email scan of International Network of Agencies
for Health Technology Assessment (INAHTA) agencies
circulated in November 2011. Each organization was asked:
1. Does your agency currently undertake rapid review?
2. What timeframes do you offer for your rapid review
products?
(a) If NO, does your agency have plans to produce
rapid reviews in the future?
(b) If YES, what type of rapid review products does
your agency produce?
3. Are your rapid reviews publicly available on your
website? If so, can you please forward the URL/
address?
Screening and selection
Broad eligibility criteria were piloted on a sample of 100
database records following the literature search. These
criteria were revised to improve specificity and then ap-
plied to each title and abstract identified by one reviewer
(LAT) in a standardized manner. A second review au-
thor (SK) screened a random sample (10 %) of excluded
records. Any uncertainties were resolved by discussion
and consensus with a third review author (TC or DM).
Any candidate rapid review passing the initial selection
criteria with a definite or unclear status, along with all
potential samples identified in the grey literature search,
was obtained in full-text format. One reviewer (SK) ap-
plied the eligibility criteria and made a final decision for
inclusion.
Eligibility criteria
Due to the diversity of methodologies, production time-
lines and nomenclature used in the previous rapid
review research [1–3], we followed inclusive selection
criteria to identify candidate studies (Fig. 1).
Rapid reviews were included regardless of publication
status. The protocol was revised prior to data extraction
to limit the eligibility of rapid reviews to those produced
between January 1, 2013 and December 31, 2014. This
revision was necessary in order to obtain a manageable
sample of rapid reviews and to ensure that the samples
collected reflected current practice given the continuous
evolution of rapid review approaches between 2005 and
2014. We included all journal-published rapid reviews
meeting the eligibility criteria in the specified timeframe
and an equivalent number of agency-produced samples
located in the grey literature. Hereafter, journal-
published rapid reviews are referred to as ‘published’
while those located in the grey literature are referred to
as ‘unpublished’ rapid reviews. Where organizations pro-
duced multiple rapid reviews in a single year, a random
selection of two samples from all available 2013 or 2014
rapid reviews was made for inclusion. No more than two
samples from a single organization were included.
Data abstraction
A single reviewer (SK) abstracted data into a Microsoft
Excel 2007 spreadsheet standardized for the project. Five
samples were used to pilot the form, and revisions were
made before global extraction. Data was collected from
included rapid reviews for study characteristics (e.g.
primary author or agency, country, date posted or pub-
lished, date submitted/accepted (if applicable), number
of authors, eligibility and selection criteria, type of
research questions, purpose, type of decision under
consideration, number of outcomes, funding, use of
supplemental appendices), methodological processes
(approach, use of protocol/protocol elements reported,
number of reviewers screening/extracting/performing
assessment of research quality, search date, number of
bibliographic databases searched, date/language or
geographical filters applied to search or screening,
additional search methods employed (e.g. grey literature,
hand searching, trial registries, citation mapping) instru-
ments used for quality assessment, use of Grading of
Recommendations Assessment, Development and Evalu-
ation (GRADE), types of study included, use of internal
or external peer-review), author-reported limitations or
disclaimers, rapid review definitions and nomenclature,
length of report (in pages) and time frames for comple-
tion where reported. We also assessed if findings were
framed in context with any reported decision-making
need.
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In the case where unpublished rapid review methods
were not reported or a source document was referenced,
agency and organization websites were checked for add-
itional clarification of process. Details on methods or
approach were extracted from additional source docu-
ments if described in such a way that no variation in
process was expected and the process for all rapid
review products was standardized and clear. Data were
not used if the associated documentation stated that that
the method was used ‘sometimes’ or that methods were
report-specific.
Data synthesis and quality appraisal
Data were extracted for published and unpublished rapid
reviews separately and then aggregated into a single
table for evaluation. Variables were synthesized narra-
tively and summarized using descriptive statistics (fre-
quencies, proportions and percentages) and category
groupings (e.g. number of authors, length in pages).
Two dimensions of rapid review reporting and meth-
odological conduct were explored. First, we applied the
A Measurement Tool to Assess Systematic Reviews
(AMSTAR) checklist, an 11-item measurement tool vali-
dated to critically appraise the methodological quality of
systematic reviews using currently understood know-
ledge on bias potentially introduced through conduct in
evidence synthesis. We used the AMSTAR checklist to
evaluate each included review to examine the overall,
and by-item, quality of conduct. Response options for
each domain were ‘yes’, ‘no’, ‘can’t answer’ and ‘not applic-
able’, and domains that were partially answered were
recorded by noting which item was answered adequately.
We counted each sufficiently reported domain (answer
= ‘yes’) and summed responses based on a maximum
possible count of 11.
Next, we evaluated the reporting quality of the rapid
review samples using the PRISMA statement. The
PRISMA statement is a 27-item (and 4-item flow dia-
gram) measure of overall reporting strength for evidence
syntheses reporting randomized controlled trials (RCTs).
We chose this instrument as it is widely accepted as a
scientific standard for reporting of secondary studies of
RCTs that can also be applied to other types of research,
including healthcare interventions. Response options for
each item were ‘yes’, ‘no’ and ‘not applicable’, and we re-
corded items that were partially answered (e.g. for item
5, if the use of a protocol was mentioned but no regis-
tration number was provided). Each included study was
evaluated individually, and we counted each sufficiently
reported item (answer = ‘yes’) and summed responses
based on a maximum possible count of 27.
Overall compliance with PRISMA and AMSTAR were
calculated as an overall sum of adequately met items for
each rapid review, a mean or median numbers of items
Fig. 1 Eligibility criteria for rapid review selection
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reported adequately across all included rapid reviews
(overall and by domain), and then stratified by publica-
tion status for exploratory analysis.
We explored the potential confounding effect of
journal word limits (represented by length in pages)
and the impact of time to completion on the number
of PRISMA or AMSTAR items adequately reported or
met. We carried out univariate regression in Micro-
soft Office Excel 2007 using the ‘Real Statistics’ data
add-in (www.real-statistics.com). Extracted data on
the length of the publication (in pages, excluding ref-
erences and appendices) and reported times to
completion for all included studies were used. Rapid
reviews were stratified by publication status for
additional analyses and documented the proportion of
adequately reported PRISMA and AMSTAR checklist
items.
Results
Selection of rapid review samples
Fourteen HTA agencies responded to the INAHTA scan,
and their external web sites were searched for relevant
rapid review products following the search for published
and unpublished reports. The literature search yielded
5478 titles and abstracts after deduplication across
databases. In total, 1008 articles were potentially relevant
and their full-text was reviewed. Few rapid review
samples in the published literature were located prior to
2011; however, samples of unpublished rapid reviews
were plentiful. Following full-text review, 66 rapid
reviews produced between 2013 and 2014 fulfilled our
eligibility criteria and were included [12–77]. Thirty-
three were journal-published [12–44] and 33 were
unpublished [45–77] rapid reviews. See Additional file
2 for a full list of included and excluded studies.
Figure 2 shows a flow diagram of studies included
using guidance from the PRISMA statement [78].
Four hundred unpublished rapid reviews met all other
eligibility criteria but were not selected with the
majority produced by a small number of agencies
who author a high volume of rapid reviews per year
e.g. (CADTH). The thirty-three published rapid
reviews included were reported in 43 published arti-
cles together with companion studies [79–86] for one
included rapid review that was published in a journal
as a series of 10 articles [19]. We considered these
publications a single rapid review as they reported
results by intervention from a single literature search.
Thirty-one unpublished rapid reviews were located
on the websites of their producing agency or
organization. Two unpublished rapid reviews [72, 76]
were located through contact with primary authors
following expert input.
Characteristics of rapid reviews
Table 1 summarizes characteristics of the included rapid
reviews. Detailed characteristics could not be reported
and explored fully in this study and are reported else-
where.1 Sixty-six rapid reviews were included. Thirty-
three were published in 25 unique journals, and the
remaining 33 were produced by 31 unique evidence pro-
ducers, including HTA agencies, academic research
groups or international, national or local agencies. The
number of rapid reviews published in peer-reviewed
journals significantly increased between 2013 and 2014.
All published rapid reviews and a majority (88 %) of the
included unpublished samples self-identified as a rapid
review somewhere in the title, abstract or body of the re-
port. Unpublished studies that did not self-identify as a
rapid review were categorized or labelled as a rapid re-
view by their associated agency or organization website
through a product description or additional source
documentation. The most common countries of produc-
tion were Canada, USA, the UK and Australia. The
number of authors varied greatly amongst the included
rapid reviews. Single authorship (a single named individ-
ual or attribution to the producing agency only with no
individual listing of authors) was found only in the
unpublished rapid review samples.
Nomenclature used to describe the accelerated or
timely evidence synthesis process varied greatly amongst
Fig. 2 PRISMA flow diagram
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Table 1 Characteristics of the included rapid reviews (n = 66)
Characteristic Published (n = 33) Unpublished (n = 33) All (n = 66)
Year of production, n (%)
2013 8 (24) 11 (33)a 19 (29)
2014 25 (76) 22 (67)a 47 (71)
Number of authors, n (%)
1 0 (0) 3 (9) 3 (5)
2–4 14 (42) 11 (33) 25 (38)
5–8 13 (39) 5 (15) 18 (27)
>8 6 (18) 5 (15) 11 (17)
Not reported 0 (0) 9 (12) 9 (14)
Self-identifies as a rapid review, n (%)
Yes 33 (100) 29 (88) 62 (94)
No 0 (0) 4 (12) 4 (6)
Country, n (%)
Canada 5 (15) 13 (39) 18 (27)
USA 4 (12) 3 (9) 7 (11)
UK 11 (33) 9 (27) 20 (31)
Australia 4 (12) 5 (15) 9 (14)
Netherlands 6 (18) 0 (0) 6 (9)
Korea 1 (3) 0 (0) 1 (2)
Switzerland 0 (0) 1 (3) 1 (2)
Malaysia 0 (0) 1 (3) 1 (2)
Various 2 (6) 1 (3) 3 (5)
Rapid review definition, n (%)
Cited 20 (60) 10 (30) 30 (46)
Own 0 (0) 6 (18) 6 (9)
Not reported 13 (40) 17 (52) 30 (46)
Nomenclature, n (%)b
Rapid review 14 (15) 10 (30) 24 (36)
Rapid systematic review 9 (12) 1 (3) 10 (15)
Rapid evidence assessment 6 (18) 4 (12) 10 (15)
Rapid evidence synthesis 2 (6) 1 (3) 3 (5)
Rapid synthesis 0 (0) 1 (3) 1 (2)
Rapid review of systematic reviews 1 (3) 1 (3) 2 (3)
Systematic rapid evidence assessment 1 (3) 0 (0) 1 (2)
Evidence-based analysis 0 (0) 1 (3) 1 (2)
Rapid response 0 (0) 2 (6) 2 (3)
Rapid evidence report/review 0 (0) 6 (18) 6 (9)
Evidence briefing 0 (0) 1 (3) 1 (2)
Evidence map 0 (0) 1 (3) 1 (2)
Rapid advice guideline 0 (0) 1 (3) 1 (2)
Systematic rapid evidence review 0 (0) 1 (3) 1 (2)
None used 0 (0) 1 (3) 1 (2)
Research questionc, n (%)
Clinical efficacy 18 (55) 22 (67) 40 (61)
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the included studies. The terms ‘rapid review’ (36 %),
‘rapid systematic review’ (15 %) or ‘rapid evidence as-
sessment’ (15 %) were most common. Over 60 % of the
research questions were aimed at the clinical efficacy or
effectiveness of an intervention. Health economics, cost
questions and those related to healthcare systems or ser-
vice delivery were also frequent. Few samples addressed
questions related to diagnostic or screening tests. A large
proportion (88 %) of the included studies narratively
summarized results.
Twelve [17, 18, 26, 29, 32–34, 50, 64, 74, 76] studies
considered meta-analysis, but data was insufficient for
pooling which necessitated a narrative summary of re-
sults. Four [17, 26, 64, 74] rapid reviews conducted
meta-analysis, and a single review conducted an indirect
treatment comparison [76]. None of the included studies
reported mentioned PRISMA or AMSTAR guidelines in
their report, although one study did report using
PRISMA-P guidelines for their protocol [76]. Included
rapid reviews had a mean length in pages of 18.7 (stand-
ard deviation (SD) = 21.7) without considering references
and appendices. Twelve percent (n = 3) of the journals
publishing the included rapid reviews required PRISMA
in their instructions to authors. We were unable to as-
certain if any of the agencies or groups producing un-
published rapid reviews endorsed PRISMA or AMSTAR
use.
Length of time taken to complete a rapid review
Although 98 % of our included samples used language
describing rapid, accelerated or timely conduct and
reporting of an evidence synthesis, very few reported
Table 1 Characteristics of the included rapid reviews (n = 66) (Continued)
Clinical effectiveness 16 (48) 25 (76) 41 (62)
Safety 13 (30) 15 (45) 28 (42)
Diagnostic/screening test 2 (6) 1 (3) 3 (5)
Health economics/cost 4 (12) 14 (42) 18 (27)
Guidelines 1 (3) 7 (21) 8 (12)
Public health 6 (18) 5 (15) 11 (17)
Health systems 9 (27) 11 (33) 20 (30)
Health policy 5 (15) 3 (9) 8 (12)
Service delivery 9 (27) 12 (36) 21 (32)
Otherd 5 (15) 5 (15) 10 (15)
Synthesis method, n (%)
Narrative 31 (94) 27 (82) 58 (88)
Meta-analysis 2 (6) 2 (6) 4 (6)
Indirect comparison 0 (0) 1 (3) 3 (5)
Economic evaluation 0 (0)e 0 (0) 0 (0)
None (no studies located) 0 (0) 3 (9) 3 (5)
Length of publication, number of pagesf, n (%)
1–5 5 (15) 3 (9) 8 (12)
6–10 17 (52) 6 (18) 23 (35)
11–15 9 (27)g 3 (9) 12 (18)
16–20 2 (6) 5 (15) 7 (11)
20–50 0 (0) 10 (30) 10 (15)
>50 0 (0) 6 (18) 6 (9)
Length of publication, mean (SD) 8.8 (4.03) 22.8 (27.2) 18.7 (21.7)
RR rapid review, SD standard deviation
aProportion matched by year and limited in number by those published, proportion does not reflect the actual number of unpublished rapid reviews
bFor unpublished refers to the terminology used to describe the methodology employed, not the product name assigned by the organization. Some publication
identified by multiple names, but this data reflects the most commonly used term in the publication
cMultiple research questions per rapid review
dQuality indicators, epidemiological associations, healthcare study methodology, patient experience
eA single study in the published group did a narrative of economic evaluations, other simply analysed costs reported. No study did a de novo
economic evaluation
fWithout references or appendices, including figures. One unpublished report was a webpage only and was counted as five pages approximated to its content.
Results sum the number and percentage of rapid reviews in each page range
gMean across 10 included multiple publications for the same RR used
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how long it took to carry out the review. Three of the
published rapid reviews [12, 29, 33] reported time to
completion of 6 weeks (n = 2) or 8 weeks (n = 1). Eight
of the unpublished rapid reviews reported actual time to
completion [47, 48, 58–60, 66, 70, 77] of between 3 and
18 weeks (mean 9.9, SD 4.8).
In published samples that did not report time to com-
pletion, we estimated duration in weeks through the use
of the date of the literature search and calculated the
number of days before the review was submitted to a
journal. In 21 samples that reported both a date for the
literature search and for journal submission, the mean
time to completion was 36.3 weeks (SD 25.8).
Methodological quality of rapid reviews: compliance with
the AMSTAR checklist
Figure 3 shows the proportion of rapid reviews (n = 66)
that adequately met the individual AMSTAR checklist
domains. Overall, compliance with the 11 items was
poor. The median number of AMSTAR domains fulfilled
was 4 (interquartile range (IQR) = 2.5 to 6.0) out of the
maximum possible 11 items. Domains were adequately
met 39 % of the time, on average, in the 66 included
rapid review samples.
Items that were better reported than others were the
appropriateness of the methods used to combine the
findings of studies (item 9, 91 %), the aggregated study
characteristics (item 6, 61 %), assessment and documen-
tation of study quality (item 7, 52 %), appropriately
forming conclusions based on the quality of the included
studies (item 8, 48 %) and listing study sources of fund-
ing (item 11, 52 %). Compliance was extremely poor for
the inclusion of a priori design of the research ques-
tion(s) and inclusion criteria (item 1, 24 %), duplicate
study selection and extraction (item 2, 15 %), use of the
publication status as an inclusion criterion (item 4,
36 %) and providing a list of included and excluded
studies (item 5, 9 %). Further exploration of item 2
(duplicate study selection and extraction) showed that
23 % of rapid reviews limited either study selection or
data extraction to a single reviewer (with or without
checking by a second reviewer) and only partially met
this domain. Seventy-four percent of rapid reviews par-
tially met item 5 by providing references for included
Fig. 3 Star chart depicting proportions of rapid reviews adequately reporting AMSTAR items (n = 66). COI conflict of interest
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studies but not excluded studies. Only two rapid reviews
[58, 59] reported any formal assessment of publication
bias, and none presented any graphical aids (e.g. funnel
plot) to support their evaluation.
Variables associated with AMSTAR reporting
Exploratory univariate regression for AMSTAR could
not be carried out for any variable as the data for the 66
included rapid review samples did not satisfy the nor-
mality assumption according to a Shapiro-Wilk test.
Square root and logarithmic data transformations were
attempted but did not normalize the distribution.
The smaller set of 11 rapid reviews reporting time to
completion was normally distributed according to a
Shapiro-Wilk test. Results of the exploratory regression
on this variable showed that longer time to completion
was significantly associated with an increase in the num-
ber of AMSTAR domains met (regression coefficient 1.7,
95 % confidence interval (CI) 0.2 to 3.2).
Reporting of rapid reviews stratified by publication
status: compliance with the AMSTAR checklist
The mean number of AMSTAR domains adequately met
for published rapid reviews was 4.2 (SD 2.2) out of the
maximum possible of 11 and 4.3 when unpublished (SD
2.5). Table 2 reports the proportion of published and un-
published rapid reviews meeting individual AMSTAR
domain specifications (answer = ‘yes’). A higher propor-
tion of unpublished rapid reviews provided an a priori
design (item 1) and searched for reports regardless of
their publication type (grey literature, item 4) when
compared to published reviews, although none of the 66
included rapid reviews reported this more than one third
of the time. Higher proportions of published rapid re-
views met the AMSTAR requirements for appropriately
combining the findings of studies (item 9) and for de-
claring sources of support through conflict of interest
statements (item 11). Poor reporting of excluded studies
led to extremely low number of ‘yes’ responses for item
5 in all rapid reviews, and similar proportions of rapid
reviews met AMSTAR domain requirements for the
reporting of literature searches (Fig. 4). Many rapid
reviews received ‘partial’ responses for this domain as
two or more databases were searched in a large propor-
tion of rapid reviews; however, they did not employ sup-
plementary strategies, or methods were so restricted
(e.g. searched only 2 years of literature) that the strategy
could not be considered comprehensive to fulfil this do-
main requirement in the studies evaluated.
Variables associated with AMSTAR reporting, stratified by
publication status
Results from a univariate regression on the length of
publication (in pages) showed no association with num-
ber of overall AMSTAR items fulfilled when published
rapid reviews were analysed. Data for the unpublished
rapid review samples were normalized using a square
root transformation prior to analysis. Regression coeffi-
cients showed a significant association (regression coeffi-
cient 6.2 (95 % CI 2.99 to 9.43)) between the length of
report and the total number of AMSTAR items met.
The sample size of rapid reviews reporting time to com-
pletion (n = 11) was insufficient for regression analyses.
Reporting of rapid reviews: compliance with the PRISMA
statement
The mean number of adequately reported PRISMA
items was 13.2 (SD 6.0) out of the maximum possible
27. Items were adequately reported 49 % of the time on
average in the 66 included rapid review samples. Figure 5
shows the proportion of rapid reviews that adequately
reported the individual PRISMA checklist items. Individ-
ual items that were reported well in a large proportion
of rapid reviews were the following: describing all infor-
mation sources in the search (item 7, 81 %), presenting
the main results of the review in a synthesis of results
Table 2 Comparison of compliance to conduct standards outlined by AMSTAR
Item Published (n = 33) (%) Unpublished (n = 33) (%)
1. Was an ‘a priori’ design provided? 15.2 33.3
2. Was there duplicate study selection and data extraction? 21.2 9.1
3. Was a comprehensive literature search performed? 42.4 30.3
4. Was the status of publication (i.e. grey literature) used as an inclusion criterion? 24.2 48.5
5. Was a list of studies (included and excluded) provided? 3.0 15.2
6. Were the characteristics of the included studies provided? 48.5 72.7
7. Was the scientific quality of the included studies assessed and documented? 54.5 48.5
8. Was the scientific quality of the included studies used appropriately in formulating conclusions? 51.5 45.5
9. Were the methods used to combine the findings of studies appropriate? 100 81.8
10. Was the likelihood of publication bias assessed? 0.0 6.1
11. Was the conflict of interest included? 69.7 33.3
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Fig. 4 Star chart depicting proportions of rapid reviews adequately reporting AMSTAR checklist items, by publication status (n = 66: n = 33
published, n = 33 unpublished). COI conflict of interest
Fig. 5 Star chart depicting proportions of rapid reviews meeting PRISMA reporting guidelines by item (n = 66)
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(item 21, 88 %), summarizing the main findings with
relevance to key groups (item 24, 74 %) and providing
general interpretation and context for the results of the
review in the conclusions (item 26, 89 %). Other items
were very poorly reported, such as indicating if a proto-
col exists or is registered (item 5, 6 %), describing the
process of data collection (item 10, 30 %) and discussing
the study limitations at the study/outcome and review
level (item 25, 40 %). Less than 50 % of rapid reviews de-
scribed the methods used for assessing risk of bias in in-
dividual studies (item 12, 44 %) or presented data on the
risk of bias in each study (item 19, 48 %).
Due to the narrative description of results in most of
the included rapid review samples, items 16 (additional
analyses—methods, 6 %) and 23 (additional analyses—-
results, 8 %) were often given responses of ‘not applic-
able’ in the rapid review samples. Summary measures
(item 13) were also poorly reported in a large proportion
of included studies. Of the 14 rapid reviews who stated
their intention to carry out meta-analyses in their
methods, only 4 (29 %) reported the effect measure that
would be considered in their analyses. Three included
unpublished rapid reviews were ‘empty’, meaning that no
candidate studies met the eligibility requirements.
A total number of PRISMA items reported by rapid
review were used in a subsequent exploratory regression
as the data were normally distributed according to a
Shapiro-Wilk test (with some negative skewness and
kurtosis).
Variables associated with PRISMA reporting
Exploratory regression analyses were carried out for the
total number of PRISMA items adequately reported
using report length and time to completion as variables.
The length of the primary publication in pages (without
appendices or references) was associated with an in-
crease of 1.45 PRISMA items adequately reported (95 %
CI 0.6 to 2.3). A smaller set of rapid reviews (n = 11)
reporting time to completion did not find a significant
correlation between the number of weeks required to
complete a rapid review and the number of PRISMA
checklist items adequately reported (regression coeffi-
cient 0.23 (95 % CI −0.27 to 0.72)).
Reporting of rapid reviews stratified by publication
status: compliance with the PRISMA statement
The mean number of adequately reported PRISMA
items for published rapid reviews was 14.5 (SD 4.7) out
of the maximum possible 27 and 11.7 when unpublished
(SD 6.8). Items were adequately reported 53 % of the
time, on average, in the 33 included published rapid re-
view samples and 44 % of the time in unpublished sam-
ples. Table 3 shows the results of a comparison of total
number rapid reviews adequately reporting PRISMA
items, stratified by publication status. PRISMA items are
better reported in published rapid reviews for the five
categories: identifying the report as a rapid or acceler-
ated evidence synthesis (a slight modification to the item
for the purposes of this review) in the title (item 1),
using a structured abstract (without protocol registration
number considered) (item 2), stating the selection
process for inclusion of studies (item 9), providing a
general interpretation of results in the form of conclu-
sions (item 26) and declaring sources of funding for the
rapid review (item 27). Published rapid reviews more
often described information sources, syntheses of results,
results of the study selection process and synthesis of re-
sults (Fig. 6). Unpublished rapid reviews were more
likely to clearly state eligibility criteria (item 6) for article
selection and present a full electronic search strategy
(item 8) and study characteristics (item 18). Rapid re-
views reported study rationale, risk of bias methods and
results, synthesis of results and summaries of evidence
equally, regardless of publication status.
Variables associated with PRISMA reporting, stratified by
publication status
A number of PRISMA items adequately reported were
analysed in a subsequent exploratory regression stratified
by publication status as the data were normally distrib-
uted according to a Shapiro-Wilk test. Separate univari-
ate regression analyses were carried out for the PRISMA
item compliance using the length of report and time to
completion as variables, stratified by publication status.
Results for the published rapid review samples showed
that the length of the primary publication was associated
with a significant increase in PRISMA items adequately
reported (regression coefficient 0.4, 95 % CI 0.1–0.6).
The length of publication in the unpublished samples
was associated with a larger increase in adequately re-
ported PRISMA items (regression coefficient 2.5, 95 %
CI 1.3–3.6).
Discussion
Our study provides a comprehensive assessment of the
design and reporting characteristics of a large, recent co-
hort of rapid reviews. A detailed examination of baseline
characteristics showed a heterogeneous mix of nomencla-
ture, research questions and approaches to rapid reviews
from a relatively small number of countries. The rapid re-
view samples showed poor compliance with both the
PRISMA and AMSTAR checklists. Only selected items in
both instruments were adequately addressed by any rapid
review. Stratification by publication status revealed that a
higher proportion of published rapid reviews adequately
complied with PRISMA guidelines compared to the un-
published samples. There was no difference in the number
of AMSTAR domains met when publication status was
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considered. There was evidence of an association between
the length of publication (PRISMA) and time to comple-
tion (AMSTAR) on the total number of items reported or
met in this cohort of rapid reviews. This relationship with
the length of report was reciprocated when the rapid re-
views were stratified by publication status. To our know-
ledge, this is the first study to explore the compliance of
rapid reviews with the PRISMA and AMSTAR
instruments or any other standardized tool that captures
adequacy of reporting and conduct. No other publications
have aimed to study published rapid reviews or make
comparisons taking publication status into consideration.
This research follows previous studies examining the
transparency of process and quality of reporting in rapid
reviews without the use of standardized tools or instru-
ments. In line with the results of previous work, many of
the identified studies did not report methods in suffi-
cient detail [1, 3, 5], a problem not unique to rapid re-
views [87]. Although there were differences in the
number of PRISMA and AMSTAR items met when pub-
lished and unpublished reviews were considered separ-
ately, the limited details reported in the rapid reviews
prevented a comprehensive evaluation in some domains,
notably literature search, quality assessment, screening,
selection and extraction, all of which are important con-
tributors to the reproducibility and evaluation of a
review. Any or all of these components may be tailored
or even omitted as part of the streamlining processes
designed to expedite systematic review completion times
[3] so were unable to ascertain whether the reporting
omissions were attributable to the rapid review approach
or simply poor reporting [88]. Evaluations of reporting
characteristics in systematic reviews and meta-analyses
have noted similar shortcomings as were found in this
study, especially in non-Cochrane reviews [88–90].
Research protocols are a key feature of systematic re-
views, and their absence leaves rapid reviews open to se-
lective reporting of results or conclusions and facilitates
post hoc modifications of approach [91]. Our findings
show that few rapid review authors are reporting the use
of protocols in their publications and even fewer are reg-
istering or publishing them. This is reflected in the poor
compliance with related items in both the PRISMA and
AMSTAR checklists. Our results conflict with a recent
report by Polisena et al. who reported a cross-sectional
review of processes and methods based on a survey of
29 international rapid review programmes [4]. Their re-
sults showed that 96.6 % (n = 28) of the agencies queried
incorporated protocol development into their rapid re-
view process. Many of the rapid reviews included in this
study were produced by the agencies and organizations
in the Polisena survey. There are a number of reasons
that authors or organizations may choose not register
their rapid review protocols, including the belief that
systems like PROSPERO are for systematic reviews only,
which emphasizes the viewpoint that a rapid review is
not a systematic review [7]. Authors of rapid reviews
may use a more condensed version of a protocol to en-
sure a timely start to the review process, but we were
unable to assess this in our samples. Rapid reviews also
show variety in the types of study questions they answer,
including public health, health services and system
Table 3 Comparison of compliance to PRISMA reporting
guidelines
PRISMA item Published
(n = 33) (%)
Unpublished
(n = 33) (%)
Title
1. Self-reports as a rapid review 84.85 48.48
Abstract
2. Structured summary 93.94 12.12
Introduction
3. Rationale 87.88 78.79
4. Objectives 69.70 48.48
Methods
5. Protocol and registration 3.03 9.09
6. Eligibility criteria 48.48 57.58
7. Information sources 90.91 72.73
8. Search 69.70 72.73
9. Study selection 63.64 45.45
10. Data collection process 36.36 24.24
11. Data items 39.39 33.33
12. ROB in individual studies 45.45 42.42
13. Summary measures 25.00* 50.00*
14. Synthesis of results 63.64 42.42
15. ROB across studies 30.30 33.33
16. Additional analyses 3.03 9.09
Results
17. Study selection 75.76 30.30
18. Study characteristics 48.48 57.58
19. ROB within studies 48.48 48.48
20. Results of individual studies 42.42 57.58
21. Synthesis of results 93.94 81.82
22. ROB across studies 18.18 30.30
23. Additional analysis 3.03 12.12
Discussion
24. Summary of evidence 75.76 72.73
25. Limitations 39.39 39.39
26. Conclusions 100.0 78.79
Funding
27. Funding 64.64 39.39
*Indicates that statistic was calculated only for rapid reviews that aimed to
perform statistical synthesis/meta-analysis
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questions. Applicability of PROSPERO or Preferred
Reporting Items for Systematic Review and Meta-
Analysis for protocols (PRISMA-P) guidance outside of
the realm of therapeutic efficacy may be questioned [92],
although they may still provide useful guidance to au-
thors of rapid reviews [93].
It is concerning that the reporting of limitations spe-
cific to the conduct of the rapid review was consistently
poor given the inherent methodological tailoring which
motivates the approach; however, this finding is consist-
ent with previous work. Ganann et al. also found that
very few rapid reviews discussed potential limitations or
any potential bias that may have been introduced due to
methodological concessions [1]. Some rapid reviews in
this study reported limitations, but a large proportion
highlighted issues related to the quality of the included
studies rather than weaknesses in approach or conduct.
Disclaimers were used, most often in unpublished re-
ports, to highlight caveats to end-users; however, most
focused on the currency of the review or vaguely refer-
enced that the review could not be considered compre-
hensive. It is particularly important for rapid reviews to
have a comprehensive limitation section to enable the
end-user to judge the validity of the methods employed,
the studies included and ultimately how applicable the
findings of the review may be for their own purposes.
Less than half of rapid reviews reported a structured
summary or abstract. When the rapid review samples
were stratified by their publication status, results chan-
ged significantly. We found that almost all journal-
published samples reported structured abstracts, as is
usually required by the journal, while few unpublished
samples did. Many of the unpublished rapid reviews did
use executive summaries to highlight key findings; how-
ever, most were either too lengthy to provide the reader
with the intended brief overview of the report and did
not summarize methods in any capacity. This may be at-
tributable to the different aim of unpublished rapid re-
views, which may be presented to end-users alongside
additional support documentation (e.g. research sum-
mary document). It is probable that these rapid reviews
are not aimed at being a stand-alone product like a jour-
nal article [94]. Still, the Organization for Economic Co-
operation and Development (OECD) and others still
highlight the need for key messages over and beyond the
executive summary as they often cannot read detailed
the findings from HTA products and must have critical
messages communicated for better knowledge transla-
tion and uptake [94, 95].
Although closely related, it is important to keep the
concepts of reporting and conduct separate when con-
sidering these findings. The low number of items com-
pletely met, and large proportion of domains of partially
met for AMSTAR may be attributable to more stringent
or rigid assessment requirements (when compared to
items in PRISMA). For example, the use of single
Fig. 6 Star chart depicting proportions of rapid reviews adequately reporting PRISMA items, by publication status (n = 66: n = 33 published,
n = 33 unpublished)
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reviewers to screen literature or extract data resulted in
low number of AMSTAR items adequately meeting
related domains. It is possible that a more granular
AMSTAR assessment criterion would capture the meth-
odological tailoring intrinsic to rapid reviews in a way
that is more descriptive to the end-user. Further detail
on the individual methods tailored in a rapid review, if
captured by AMSTAR, would allow for more careful
consideration of what is acceptable or not and where
bias, if any, was likely to be introduced. It may be useful
to have subdomains for item 1 where the use of a proto-
col would be kept separate from the description of eligi-
bility criteria or the PICO, item 2 (duplicate study
selection and data extraction) or item 5 (list of included
and excluded studies). While not aimed at rapid reviews,
a modification to the AMSTAR checklist in the form of
R (revised)-AMSTAR has been proposed and validated
[96] but was not developed or endorsed by the AMSTAR
research group. R-AMSTAR considers three to four more
detailed criteria per original AMSTAR item, which in
principle may be more applicable to assessment of rapid
reviews. This tool was later assessed to have poor meas-
urement properties compared to the original instrument
in a sample of systematic reviews, so further research or
revision may be required before investigation of its use
can be considered [96, 97].
Regression models were used to explore the influence
of article length and completion time on the number of
PRISMA and AMSTAR items adequately reported or
met. Longer manuscript length was associated with
higher compliance with PRISMA guidelines while
AMSTAR compliance increased with time to comple-
tion. No previous studies have assessed rapid reviews
using these methods, so there is little evidence to aid
with interpretation of the significance of this result.
Findings suggest reporting quality is compromised when
not enough space is provided for a fulsome description.
Results from a study on the reporting of meta-analyses
of surgical interventions had similar findings [89] and
demonstrate that this is not a problem specific to rapid
reviews alone.
The term ‘rapid review’ implies that time is a signifi-
cant factor in the conduct and reporting of this evidence
synthesis approach. The influence of time was significant
in our regression, and rapid reviews with longer time to
completion (in weeks) showed a higher proportion of
PRISMA and AMSTAR items adequately reported or
met. Harker and Kleijnen examined a sample of rapid
reviews and estimated time taken to complete based on
the last search date and date published [3]. Their results
showed a significant association between the length of
time taken and the number of rapid review methodolo-
gies that reported clearly and closely adhered to recom-
mended systematic review guidelines from Cochrane or
the York Centre for Reviews and Dissemination (CRD).
This empirical evidence may actually conflict with the
stance of researchers and knowledge users on this topic.
In a recent study on research producer and healthcare
decision-maker opinions and attitudes towards rapid re-
views, Kelly et al. (2015, under review) noted there is a
salient viewpoint amongst this mixed group of evidence
producers and knowledge users that reduced review time
is not necessarily associated with a lower quality of re-
view and they asserted that quality can be maintained
even when rigour is reduced. Our analyses did not take
into account the differences in rapid review approach. It
may be more sensible to consider reporting and conduct
of rapid reviews while also examining the variation in re-
view approach (from an evidence brief or map to a fully
comprehensive report that resembles a systematic review
in almost all facets) which may also influence time to
completion. Data were insufficient to explore these
factors through multiple regression, but this may be a
valuable research objective going forward.
Strengths and limitations
The strengths of this research include a protocol-driven
design (available on request through the corresponding
author), a complete and far ranging search and a
detailed exploration into the reporting and conduct of
rapid reviews.
Limitations of this study may influence the interpret-
ation and applicability of our findings. Due to the
diversity of approaches, timelines and nomenclature
employed by rapid review producers, it was difficult to
apply a standardized selection criteria and some subject-
ivity by the reviewers may have influenced inclusion of
candidate rapid reviews. Specifically, the eligibility criter-
ion of 9 months for the time to completion of rapid re-
views was difficult to apply; therefore, most reviews met
the inclusion criteria by self-identifying as an acceler-
ated, rapid or timely review of evidence in the title, ab-
stract or full-text. As we were unable to corroborate
time to completion in most articles, we cannot exclude
that some producers may have undertaken comprehen-
sive systematic reviews (with little tailoring of methods)
in an accelerated fashion using additional resources. Al-
though Moher et al. acknowledge that this approach
may still be a type of rapid review, the inclusion of these
comprehensive but timely reports may skew the study of
the tailored methods [93].
Similarly, the noted heterogeneity of terminology may
have led to some rapid reviews being missed. Although
we limited the rapid reviews we retrieved to a cross
section of samples from 2013 and 2014, we believe we
captured a comprehensive representation of reviews in
both the published and grey literature. The addition of
the INAHTA scan also supplemented our search and
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identified smaller organizations producing rapid reviews
that helped add to our unpublished samples. Addition-
ally, when the protocol was amended to restrict the date
of publication for the included rapid reviews to 2013
and 2014, some rapid review producers were omitted
from the sample, having not published rapid reviews
within our eligibility timeline. This necessitated the in-
clusion of two rapid review samples each from two HTA
producers (CADTH, Health Quality Ontario).
In this study, we explored two influential variables and
their association with the PRISMA and AMSTAR check-
lists through univariate regression. Further exploration
of other influential variables is warranted including the
inclusion of primary or secondary studies (or both), type
of research questions, purpose or type of rapid review
approach or journal factors such as PRISMA endorse-
ment or impact factor. In addition, looking at the total
aggregate number of items adequately reported or met
for both instruments as absolute measures of compli-
ance is a weakness. These summary totals have limited
utility to end-users, as there is currently no accepted
cut-off denoting low, moderate or high quality of con-
duct or reporting based on these totals. We have de-
scribed individual domain compliance in an effort to
make results more practical and to facilitate interpret-
ation in the context of rapid reviews. These instruments
were designed for use with systematic reviews and meta-
analyses of therapeutic interventions, and it could be ar-
gued that measuring our sample rapid reviews involving
a variety of research question types on the same scale is
unfair. However, there are limited studies comparing the
methods of rapid reviews to those of more fulsome sys-
tematic reviews [5, 98–100]. Instruments like PRISMA
or AMSTAR enable comparisons of rapid reviews in a
standardized manner to each other. This could be ex-
tended to allow for comparisons against other evidence
synthesis products. These tools provide evidence pro-
ducers with a concise, consistent way to ensure that re-
views are transparently and adequately reported to end-
users, which enables decision-makers to assess findings
they receive with confidence, especially when they must
do so urgently when decisions cannot wait.
We included three ‘empty’ rapid reviews, where no
studies of interest were eligible for inclusion. There is no
clear-cut way to assess these reviews, and although some
have suggested these studies should be excluded, we
elected to include them [101]. Although AMSTAR and
PRISMA compliance was low in these samples, these
empty reviews are valuable to end-users as they highlight
knowledge gaps, communicate topics to reduce duplica-
tion and indicate that state of evidence at a certain point
of time, which is often the primary objective of a rapid
review [102]. Care should be taken to prevent publica-
tion bias [103]. The authors of the empty rapid review
samples in this study still provided conclusions based on
a broader review of relevant literature but often failed to
highlight these shortcomings to the end-user. In many
of the other included rapid reviews, eligibility criteria
were expanded to consider more evidence when no
studies of a certain type were located, an iterative
process that is common in both systematic and rapid
reviews [2, 9]. Without a protocol that is posted or regis-
tered, it is difficult to assess whether these modifications
were appropriate, even when the processes are well-
described. Additionally, a series of 10 rapid reviews on
chronic pain that used a single search were included as a
single rapid review with accompanying companion arti-
cles. Although it would not have changed the results of
this study, it is worth mentioning that employing a sin-
gle search for multiple evidence reviews may be an ap-
proach used to expedite the process, and it may have
been more appropriate to consider these reviews
individually.
Conclusions
Rapid review products vary greatly, and it is compli-
cated and onerous to compare and contrast the nu-
merous approaches used. Standardized reporting and
conduct checklists such as AMSTAR and PRISMA
provide a useful way to compare and contrast rapid
reviews across a number of key domains. This assess-
ment of 66 rapid reviews shows that conduct and
reporting are often inadequate and unclear. This is a
significant limitation attributable to rapid reviews,
although this problem is not unique to this approach.
Poor descriptions of research activities result in
research that is not replicable and end-users are un-
able to sufficiently assess potential for bias in the re-
ports. Arguably, clear and complete descriptions of
conduct and transparent reporting of research activ-
ities are more important in rapid reviews as they
inherently tailor gold standard review methodology.
Editorial insistence may help to encourage compliance
in published reports; however, scientific editors, au-
thors and producing agencies all have a responsibility
to ensure that the reporting of conduct and findings
in the research products they produce or publish is
appropriate and complete. Our results show that fu-
ture research may be warranted to define reporting or
conduct guidelines specific to rapid reviews. This is
not to imply that existing guidelines are inadequate,
but further work to evaluate their adequacy for
assessing rapid reviews may be required. It is unclear
whether guidelines specific to rapid reviews are neces-
sary or desired by the evidence producers and users
and whether these types of products would be applic-
able across the spectrum of rapid review approaches.
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Endnote
1Note: The rapid review characteristics presented in
this study are free from selective reporting. The surplus
of study and methodological characteristics could not be
adequately addressed in a single manuscript and will be
explored in a future manuscript.
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